(R) -2-Arylpropionamide compounds of formula (I) are described. The processfor their preparation and pharmaceutical preparations thereof are alsodescribed. The 2-Arylpropionamides of the invention are useful in theprevention and treatment of tissue damage due to the exacerbate recruitment ofpolymorphonuclear leukocytes (Leukocytes PMN) and of monocytes at theinflammatory sites. In particular, the invention relates to the R enantiomersof omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for usein the inhibition of he chemataxis of neutrophils and monocites induced by theC5a fraction of the complement and by other chemotactic proteins whosebiological activity is associated with activation of a 7-TD receptor. Selectedcompounds of formula (I) are dual inhibitors of both the C5a-inducedchemotaxis of nutrophils and monocytes and the IL-8-induced chemotaxis of PMNleukocytes. The compounds of the invention are used in the treatment ofpsoriasis, ulcerative cholitis, glomerular nephritis, acute respiratoryinsufficiency, idiopathic fibrosis, rheumatoid arthritis and in the preventionand the treatment of injury caused by ischemia and reperfusion.
